Natera, Inc. (NASDAQ: NTRA

Join This Class Action

NEW YORK, NY –  May 4, 2022 – Wolf Haldenstein Adler Freeman & Herz LLP  announces that  a federal securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Natera, Inc. (“Natera”) (NASDAQ: NTRA) on behalf of all persons and entities who purchased or otherwise acquired Natera common stock between February 26, 2020, and April 19, 2022, inclusive (the “Class Period”). 

All investors who purchased the shares of  Natera, Inc. and incurred losses are  advised  to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774.

If you have incurred losses in Natera, Inc. you may, no later than June 27, 2022, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in Natera, Inc.

On January 1, 2022, an article from the New York Times called into question the accuracy of certain prenatal tests, including Natera’s Panorama test, alleging that positive results on tests are incorrect approximately 85 percent of the time, and that patients who receive a positive result are supposed to pursue follow-up testing, which “can cost thousands of dollars, come with a small risk of miscarriage and can’t be performed until later in pregnancy.

On this news, Natera’s stock price fell $5.35, or 5.7%, over two trading days to close at $88.04 per share on January 4, 2022.

Then, on January 14, 2022, a nonprofit watchdog group filed a complaint with the SEC requesting an investigation into whether Natera had “repeatedly” claimed that its tests were “much more reliable than it appears they really are.”

On this news, Natera’s stock fell $6.29, or 9.3%, to close at $61.08 per share on January 18, 2022.

On March 9, 2022, Hindenburg Research published a report which alleged, among other things, that Natera’s revenue growth has been “fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers.” On this news, Natera’s stock price fell $17.95, or 32.8%, to close at $36.80 per share on March 9, 2022.

Then, on March 14, 2022, a Delaware District Court jury found that Natera had engaged in false advertising, including claims that its kidney transplant test, Prospera, was more accurate than its competing tests. On this news, Natera’s stock price fell $5.57 per share, or 15.5%, to close at $30.32 per share on March 15, 2022.

Then, on April 19, 2022, the United States Food and Drug Administration (“FDA”) issued a safety communication “to educate patients an health care providers and to help reduce the inappropriate use” of non-invasive prenatal tests (“NIPT”), cautioning that NIPTs reliability and accuracy “may not be supported with sound scientific evidence,” revealing that there had been “cases where a screening test reported a genetic abnormality and a confirmatory diagnostic test later found that the fetus was healthy. On this news, Natera’s stock fell $1.53, or 3.9%, to close at $38.63 per share on April 19, 2022.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735 or via e-mail at classmember@whafh.com.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP

Patrick Donovan, Esq.

Gregory Stone, Director of Case and Financial Analysis

Email: gstone@whafh.com, donovan@whafh.com or classmember@whafh.com

Tel: (800) 575-0735 or (212) 545-4774

 


Certification and Authorization Pursuant to Federal Securities Laws

  • The individual or entity listed below requests Wolf Haldenstein Adler Freeman & Herz LLP to file an action or motion for appointment as lead plaintiff and lead counsel under the federal securities laws to recover damages and to seek other relief against Natera, Inc. (NASDAQ: NTRA. Wolf Haldenstein Adler Freeman & Herz LLP will not do so until you complete a retainer agreement authorizing us to prosecute the action on a contingent fee basis.

  • I, individually or on behalf of the entity I represent ("I"), hereby certify as follows:

    1. I have reviewed the complaint and authorize the filing of a lead plaintiff motion or action on my behalf.
    2. I did not acquire the security that is the subject of this action at the direction of the Firm or in order to participate in this private action or any other litigation under the federal securities laws.
    3. I am willing to serve as a representative party on behalf of a class, including providing testimony at deposition and trial, if necessary.
    4. I represent and warrant that I am fully authorized to enter into and execute this certification.
    5. I will not accept any payment for serving as a representative party on behalf of the class beyond my pro rata share of any recovery, except such reasonable costs and expenses (including lost wages) directly relating to the representation of the class as ordered or approved by the court.
    6. I have made no transaction(s) during the Class Period in the debt or equity securities that are the subject of this action except those set forth below:
  • Type of SecurityBuy Date (mm/dd/yy)# of SharesPrice per Share 
  • Type of SecuritySell Date (mm/dd/yy)# of SharesPrice per Share 
  • Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 07/01/2022